Trial
NCT02700022
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Diffuse Large B-cell Lymphoma
Intervention
Alisertib
Why stopped
Lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-20